<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p51" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_51{left:36px;bottom:25px;letter-spacing:0.07px;word-spacing:0.01px;}
#t2_51{left:341px;bottom:30px;}
#t3_51{left:348px;bottom:25px;letter-spacing:0.11px;}
#t4_51{left:377px;bottom:30px;}
#t5_51{left:381px;bottom:25px;letter-spacing:0.07px;word-spacing:-0.1px;}
#t6_51{left:540px;bottom:30px;}
#t7_51{left:546px;bottom:25px;letter-spacing:0.07px;}
#t8_51{left:44px;bottom:77px;letter-spacing:0.1px;word-spacing:-0.05px;}
#t9_51{left:44px;bottom:63px;letter-spacing:0.1px;}
#ta_51{left:285px;bottom:860px;letter-spacing:-0.32px;word-spacing:0.06px;}
#tb_51{left:285px;bottom:827px;letter-spacing:-0.24px;}
#tc_51{left:996px;bottom:873px;letter-spacing:-0.1px;}
#td_51{left:1043px;bottom:853px;letter-spacing:-0.22px;word-spacing:0.13px;}
#te_51{left:1093px;bottom:833px;letter-spacing:-0.09px;}
#tf_51{left:1098px;bottom:28px;letter-spacing:0.32px;}
#tg_51{left:36px;bottom:778px;letter-spacing:0.34px;word-spacing:-0.16px;}
#th_51{left:340px;bottom:778px;letter-spacing:0.32px;word-spacing:-0.31px;}
#ti_51{left:839px;bottom:778px;letter-spacing:0.28px;word-spacing:-0.12px;}
#tj_51{left:36px;bottom:535px;letter-spacing:-0.09px;}
#tk_51{left:36px;bottom:517px;letter-spacing:-0.09px;}
#tl_51{left:36px;bottom:498px;letter-spacing:-0.11px;}
#tm_51{left:36px;bottom:480px;letter-spacing:-0.09px;}
#tn_51{left:338px;bottom:748px;letter-spacing:-0.1px;}
#to_51{left:338px;bottom:729px;letter-spacing:-0.1px;}
#tp_51{left:428px;bottom:737px;letter-spacing:-0.08px;}
#tq_51{left:338px;bottom:704px;letter-spacing:-0.1px;}
#tr_51{left:338px;bottom:679px;letter-spacing:-0.13px;}
#ts_51{left:362px;bottom:686px;}
#tt_51{left:370px;bottom:679px;letter-spacing:-0.08px;}
#tu_51{left:338px;bottom:660px;letter-spacing:-0.09px;}
#tv_51{left:338px;bottom:642px;letter-spacing:-0.1px;}
#tw_51{left:338px;bottom:624px;letter-spacing:-0.1px;}
#tx_51{left:340px;bottom:548px;letter-spacing:-0.2px;}
#ty_51{left:340px;bottom:529px;letter-spacing:-0.1px;}
#tz_51{left:340px;bottom:511px;letter-spacing:-0.08px;}
#t10_51{left:340px;bottom:493px;letter-spacing:-0.08px;}
#t11_51{left:340px;bottom:474px;letter-spacing:-0.1px;}
#t12_51{left:466px;bottom:482px;}
#t13_51{left:338px;bottom:590px;letter-spacing:-0.1px;}
#t14_51{left:341px;bottom:394px;letter-spacing:-0.1px;}
#t15_51{left:341px;bottom:325px;letter-spacing:-0.09px;}
#t16_51{left:341px;bottom:307px;letter-spacing:-0.11px;}
#t17_51{left:456px;bottom:314px;letter-spacing:-0.14px;}
#t18_51{left:341px;bottom:264px;letter-spacing:-0.1px;}
#t19_51{left:339px;bottom:219px;letter-spacing:-0.08px;}
#t1a_51{left:1066px;bottom:509px;letter-spacing:-0.1px;}
#t1b_51{left:1066px;bottom:490px;letter-spacing:-0.09px;}
#t1c_51{left:1066px;bottom:472px;letter-spacing:-0.08px;}
#t1d_51{left:1072px;bottom:426px;letter-spacing:-0.09px;}
#t1e_51{left:1072px;bottom:407px;letter-spacing:-0.06px;}
#t1f_51{left:1072px;bottom:389px;letter-spacing:-0.08px;}
#t1g_51{left:1072px;bottom:371px;letter-spacing:-0.09px;}
#t1h_51{left:1072px;bottom:352px;letter-spacing:-0.25px;}
#t1i_51{left:550px;bottom:562px;letter-spacing:-0.09px;}
#t1j_51{left:550px;bottom:544px;letter-spacing:-0.09px;}
#t1k_51{left:650px;bottom:552px;}
#t1l_51{left:546px;bottom:463px;letter-spacing:-0.1px;}
#t1m_51{left:546px;bottom:444px;letter-spacing:-0.09px;}
#t1n_51{left:546px;bottom:426px;letter-spacing:-0.09px;}
#t1o_51{left:612px;bottom:433px;}
#t1p_51{left:839px;bottom:562px;letter-spacing:-0.11px;}
#t1q_51{left:940px;bottom:570px;}
#t1r_51{left:667px;bottom:516px;letter-spacing:-0.09px;}
#t1s_51{left:667px;bottom:498px;letter-spacing:-0.09px;}
#t1t_51{left:667px;bottom:479px;letter-spacing:-0.1px;}
#t1u_51{left:667px;bottom:409px;letter-spacing:-0.08px;}
#t1v_51{left:667px;bottom:391px;letter-spacing:-0.09px;}
#t1w_51{left:839px;bottom:519px;letter-spacing:-0.09px;}
#t1x_51{left:839px;bottom:501px;letter-spacing:-0.1px;}
#t1y_51{left:928px;bottom:508px;letter-spacing:-0.07px;}
#t1z_51{left:839px;bottom:482px;letter-spacing:-0.09px;}
#t20_51{left:839px;bottom:427px;letter-spacing:-0.13px;}
#t21_51{left:863px;bottom:435px;}
#t22_51{left:839px;bottom:409px;letter-spacing:-0.06px;}
#t23_51{left:839px;bottom:390px;letter-spacing:-0.1px;}
#t24_51{left:839px;bottom:372px;letter-spacing:-0.1px;}
#t25_51{left:928px;bottom:380px;letter-spacing:-0.09px;}
#t26_51{left:815px;bottom:315px;letter-spacing:-0.11px;word-spacing:-0.62px;}
#t27_51{left:1003px;bottom:315px;letter-spacing:-0.11px;}
#t28_51{left:36px;bottom:182px;}
#t29_51{left:46px;bottom:176px;letter-spacing:0.13px;}
#t2a_51{left:261px;bottom:176px;}
#t2b_51{left:36px;bottom:165px;}
#t2c_51{left:42px;bottom:159px;letter-spacing:0.13px;word-spacing:-0.06px;}
#t2d_51{left:337px;bottom:159px;}
#t2e_51{left:36px;bottom:148px;}
#t2f_51{left:42px;bottom:142px;letter-spacing:0.12px;}
#t2g_51{left:45px;bottom:125px;letter-spacing:0.11px;word-spacing:0.02px;}
#t2h_51{left:45px;bottom:108px;letter-spacing:0.12px;}
#t2i_51{left:394px;bottom:108px;letter-spacing:0.13px;}
#t2j_51{left:478px;bottom:108px;}
#t2k_51{left:622px;bottom:182px;}
#t2l_51{left:632px;bottom:176px;letter-spacing:0.12px;word-spacing:-0.03px;}
#t2m_51{left:1142px;bottom:176px;}
#t2n_51{left:622px;bottom:165px;}
#t2o_51{left:628px;bottom:159px;letter-spacing:0.09px;word-spacing:0.03px;}
#t2p_51{left:631px;bottom:142px;letter-spacing:0.11px;}
#t2q_51{left:721px;bottom:142px;letter-spacing:0.13px;word-spacing:-0.04px;}
#t2r_51{left:631px;bottom:125px;letter-spacing:0.08px;word-spacing:0.06px;}
#t2s_51{left:757px;bottom:125px;}
#t2t_51{left:622px;bottom:114px;}
#t2u_51{left:636px;bottom:108px;letter-spacing:0.12px;}
#t2v_51{left:667px;bottom:108px;letter-spacing:0.12px;}
#t2w_51{left:745px;bottom:108px;letter-spacing:0.08px;word-spacing:0.05px;}
#t2x_51{left:568px;bottom:330px;letter-spacing:-0.09px;}
#t2y_51{left:568px;bottom:312px;letter-spacing:-0.09px;}
#t2z_51{left:568px;bottom:294px;letter-spacing:-0.09px;}
#t30_51{left:568px;bottom:275px;letter-spacing:-0.11px;}
#t31_51{left:988px;bottom:706px;letter-spacing:-0.09px;}
#t32_51{left:988px;bottom:688px;letter-spacing:-0.09px;}
#t33_51{left:988px;bottom:669px;letter-spacing:-0.25px;}
#t34_51{left:560px;bottom:697px;letter-spacing:-0.1px;}
#t35_51{left:560px;bottom:677px;letter-spacing:-0.09px;}
#t36_51{left:539px;bottom:615px;letter-spacing:-0.09px;}
#t37_51{left:539px;bottom:596px;letter-spacing:-0.09px;}
#t38_51{left:694px;bottom:604px;}
#t39_51{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_51{font-size:9px;font-family:ArialMT_5tg;color:#000;}
.s1_51{font-size:5px;font-family:ArialMT_5tg;color:#000;}
.s2_51{font-size:12px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_51{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_51{font-size:17px;font-family:ArialMT_5tg;color:#0065A4;}
.s5_51{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s6_51{font-size:17px;font-family:Arial-BoldMT_jz;color:#000;}
.s7_51{font-size:14px;font-family:Arial-BoldMT_5te;color:#000;}
.s8_51{font-size:17px;font-family:Arial-BoldMT_5te;color:#0065A4;}
.s9_51{font-size:12px;font-family:ArialMT_5tg;color:#000;}
.sa_51{font-size:15px;font-family:ArialMT_5tg;color:#0065A4;}
.sb_51{font-size:15px;font-family:ArialMT_5tg;color:#000;}
.sc_51{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts51" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: Arial-BoldMT_jz;
	src: url("fonts/Arial-BoldMT_jz.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

</style>
<div id="pg51Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg51" style="-webkit-user-select: none;"><object width="1210" height="935" data="51/51.svg" type="image/svg+xml" id="pdf51" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_51" class="t s0_51">Version 4.2024, 5/1/2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_51" class="t s1_51">® </span>
<span id="t3_51" class="t s0_51">(NCCN </span>
<span id="t4_51" class="t s1_51">® </span>
<span id="t5_51" class="t s0_51">), All rights reserved. NCCN Guidelines </span>
<span id="t6_51" class="t s1_51">® </span>
<span id="t7_51" class="t s0_51">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_51" class="t s2_51">Note: All recommendations are category 2A unless otherwise indicated. </span>
<span id="t9_51" class="t s2_51">Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged. </span>
<span id="ta_51" class="t s3_51">NCCN Guidelines Version 4.2024 </span>
<span id="tb_51" class="t s3_51">Cancer of the Supraglottic Larynx </span>
<span id="tc_51" class="t s4_51">NCCN Guidelines Index </span>
<span id="td_51" class="t s4_51">Table of Contents </span>
<span id="te_51" class="t s4_51">Discussion </span>
<span id="tf_51" class="t s5_51">SUPRA-3 </span>
<span id="tg_51" class="t s5_51">CLINICAL STAGING </span><span id="th_51" class="t s5_51">TREATMENT OF PRIMARY AND NECK </span><span id="ti_51" class="t s5_51">ADJUVANT TREATMENT </span>
<span id="tj_51" class="t s6_51">Requiring </span>
<span id="tk_51" class="t s5_51">(amenable to) total </span>
<span id="tl_51" class="t s5_51">laryngectomy </span>
<span id="tm_51" class="t s5_51">(T3,N0) </span>
<span id="tn_51" class="t s5_51">Concurrent systemic </span>
<span id="to_51" class="t s5_51">therapy/RT </span>
<span id="tp_51" class="t s7_51">i,k,l </span>
<span id="tq_51" class="t s5_51">or </span>
<span id="tr_51" class="t s5_51">RT </span>
<span id="ts_51" class="t s7_51">i </span>
<span id="tt_51" class="t s5_51">if patient not </span>
<span id="tu_51" class="t s5_51">medical candidate for </span>
<span id="tv_51" class="t s5_51">concurrent systemic </span>
<span id="tw_51" class="t s5_51">therapy/RT </span>
<span id="tx_51" class="t s5_51">Laryngectomy, </span>
<span id="ty_51" class="t s5_51">thyroidectomy and </span>
<span id="tz_51" class="t s5_51">with ipsilateral, </span>
<span id="t10_51" class="t s5_51">central, or bilateral </span>
<span id="t11_51" class="t s5_51">neck dissection </span>
<span id="t12_51" class="t s7_51">h </span>
<span id="t13_51" class="t s5_51">or </span>
<span id="t14_51" class="t s5_51">or </span>
<span id="t15_51" class="t s5_51">Induction </span>
<span id="t16_51" class="t s5_51">chemotherapy </span>
<span id="t17_51" class="t s7_51">k,m </span>
<span id="t18_51" class="t s5_51">or </span>
<span id="t19_51" class="t s5_51">Clinical trials </span>
<span id="t1a_51" class="t s5_51">Follow-up </span>
<span id="t1b_51" class="t s8_51">(FOLL-A, 1 </span>
<span id="t1c_51" class="t s8_51">of 2) </span>
<span id="t1d_51" class="t s5_51">Recurrent </span>
<span id="t1e_51" class="t s5_51">or </span>
<span id="t1f_51" class="t s5_51">persistent </span>
<span id="t1g_51" class="t s5_51">disease </span>
<span id="t1h_51" class="t s8_51">(ADV-3) </span>
<span id="t1i_51" class="t s5_51">pN1 without other </span>
<span id="t1j_51" class="t s5_51">risk features </span>
<span id="t1k_51" class="t s7_51">j </span>
<span id="t1l_51" class="t s5_51">Adverse </span>
<span id="t1m_51" class="t s5_51">pathologic </span>
<span id="t1n_51" class="t s5_51">features </span>
<span id="t1o_51" class="t s7_51">j </span>
<span id="t1p_51" class="t s5_51">Consider RT </span>
<span id="t1q_51" class="t s7_51">h </span>
<span id="t1r_51" class="t s5_51">Extranodal </span>
<span id="t1s_51" class="t s5_51">extension and/or </span>
<span id="t1t_51" class="t s5_51">positive margin </span>
<span id="t1u_51" class="t s5_51">Other risk </span>
<span id="t1v_51" class="t s5_51">features </span>
<span id="t1w_51" class="t s5_51">Systemic </span>
<span id="t1x_51" class="t s5_51">therapy/RT </span>
<span id="t1y_51" class="t s7_51">i,k </span>
<span id="t1z_51" class="t s5_51">(category 1) </span>
<span id="t20_51" class="t s5_51">RT </span>
<span id="t21_51" class="t s7_51">i </span>
<span id="t22_51" class="t s5_51">or </span>
<span id="t23_51" class="t s5_51">Consider systemic </span>
<span id="t24_51" class="t s5_51">therapy/RT </span>
<span id="t25_51" class="t s7_51">i,k </span>
<span id="t26_51" class="t s5_51">Response Assessment </span><span id="t27_51" class="t s8_51">(SUPRA-7) </span>
<span id="t28_51" class="t s9_51">h </span>
<span id="t29_51" class="t sa_51">Principles of Surgery (SURG-A)</span><span id="t2a_51" class="t sb_51">. </span>
<span id="t2b_51" class="t s9_51">i </span>
<span id="t2c_51" class="t sa_51">Principles of Radiation Therapy (SUPRA-A)</span><span id="t2d_51" class="t sb_51">. </span>
<span id="t2e_51" class="t s9_51">j </span>
<span id="t2f_51" class="t sb_51">Adverse pathologic features: extranodal extension, positive margins, </span>
<span id="t2g_51" class="t sb_51">close margins, pT3 or pT4 primary, pN2 or pN3 nodal disease, perineural </span>
<span id="t2h_51" class="t sb_51">invasion, vascular invasion, and lymphatic invasion </span><span id="t2i_51" class="t sa_51">(Discussion)</span><span id="t2j_51" class="t sb_51">. </span>
<span id="t2k_51" class="t s9_51">k </span>
<span id="t2l_51" class="t sa_51">Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)</span><span id="t2m_51" class="t sb_51">. </span>
<span id="t2n_51" class="t s9_51">l </span>
<span id="t2o_51" class="t sb_51">When using concurrent systemic therapy/RT, the preferred agent is cisplatin </span>
<span id="t2p_51" class="t sb_51">(category 1). </span><span id="t2q_51" class="t sa_51">See Principles of Systemic Therapy for Non-Nasopharyngeal </span>
<span id="t2r_51" class="t sa_51">Cancers (SYST-A)</span><span id="t2s_51" class="t sb_51">. </span>
<span id="t2t_51" class="t s9_51">m </span>
<span id="t2u_51" class="t sb_51">See </span><span id="t2v_51" class="t sa_51">Discussion </span><span id="t2w_51" class="t sb_51">on induction chemotherapy. </span>
<span id="t2x_51" class="t s5_51">CT (with contrast) or </span>
<span id="t2y_51" class="t s5_51">MRI (with and without </span>
<span id="t2z_51" class="t s5_51">contrast) of primary </span>
<span id="t30_51" class="t s5_51">and neck </span>
<span id="t31_51" class="t s5_51">Recurrent or </span>
<span id="t32_51" class="t s5_51">persistent disease </span>
<span id="t33_51" class="t s8_51">(ADV-3) </span>
<span id="t34_51" class="t s8_51">Post Systemic Therapy/RT or RT </span>
<span id="t35_51" class="t s8_51">Neck Evaluation (FOLL-A, 2 of 2) </span>
<span id="t36_51" class="t s5_51">pN0 with no adverse </span>
<span id="t37_51" class="t s5_51">pathologic features </span>
<span id="t38_51" class="t s7_51">j </span>
<span id="t39_51" class="t sc_51">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
